

Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Please cancel claim 1 to 33 without prejudice or disclaimer.

Please add new claims 34 to 55 as set forth below.

Listing of Claims:

1-33 (Cancelled)

34. (New) A virus like particle (VLP) comprising Avian Influenza virus HA, NA and M1 proteins, wherein said VLP exhibits hemagglutinin or neuraminidase activity.

35. (New) The VLP of claim 34, wherein said HA, NA and M1 proteins are derived an Avian Influenza type A virus.

36. (New) The VLP of claim 35, wherein the HA or the NA is H9N2.

37. (New) The VLP of claim 35, wherein the HA and the NA is H9N2.

38. (New) A VLP of claim 34, wherein the VLP is expressed from one or more nucleic acids encoding HA, NA and M1 proteins in a eukaryotic cell under conditions which permit the formation of VLPs.

39. (New) The VLP of claim 38, wherein said eukaryotic cell is selected from the group consisting of, yeast, insect, amphibian, avian or mammalian cells.

40. (New) The VLP of claim 34, wherein said HA and NA are from an Avian Influenza virus which was isolated from an infected organism.

41. (New) The VLP of claim 34, wherein said VLP elicits neutralizing antibodies in a subject which are protective.

42. (New) The VLP of claim 34, wherein the VLP exhibits hemagglutinin and neuraminidase activity.

43. (New) The VLP of claim 34, wherein the VLP is associated with an adjuvant.
44. (New) The VLP of claim 43, wherein said adjuvant comprises Novasomes.
45. (New) The VLP of claim 34, further comprising at least one M2 or NP protein.
46. (New) The VLP of claim 41, wherein the subject is a human.
47. (New) The VLP of claim 40, wherein said infected organism is human.
48. (New) The VLP of claim 34 wherein the VLP has a diameter of 60 to 80 nm.
49. (New) The VLP of claim 34, wherein the VLP comprises surface peplomers.
50. (New) The VLP of claim 34, wherein the VLP is expressed in insect cells.
51. (New) The VLP of claim 34, wherein the avian influenza is avian influenza A/Hong Kong/1073/99 (H9N2).
52. (New) The VLP of claim 34, wherein said VLP exhibits hemagglutination activity at a titer of at least 1:500.
53. (New) The VLP of claim 34, wherein said VLP exhibits neuraminidase activity of at least an OD of 0.5 at a wavelength of 594 nm as determined chemically by measuring released sialic acid with thiobarbituric acid.
54. (New) An immunogenic composition, comprising a VLP of claim 34 or 42.
55. (New) A vaccine, comprising the VLP of claim 34 or 42.